16 results about "Ribonucleotide" patented technology

The application discloses a single cell whole genome amplification sequencing method. The application comprises the following steps: 1) separating a single cell, adding a single cell lysis solution to sufficiently lyse the single cell and digest proteins combined on the genomic DNA; 2) using a Tn5 transposome with a specific adapter sequence to fragment the DNA, while adding adapters to both ends of the fragments; 3) after end repair, using a ribonuclease to cut modified ribonucleotide residues on the adapter sequence; 4) using the adapter sequence as a primer to linearly amplify the fragmented DNA by using a single primer PCR method; and 5) adding sequencing adapters to both ends of the DNA fragments by using a chain extension and PCR method to obtain a final sequencing library. The method disclosed by the application can amplify single cell whole genome DNA with high coverage, uniformity and fidelity, and simultaneously and accurately detect chromosomal copy number variation CNV and single nucleotide mutation SNV on a single cell genome.

A gene editing system comprising: (a) a gene editor fusion protein comprising a Cas protein and a deaminase, or a nucleic acid encoding the gene editor fusion protein, and (b) a hybrid guide nucleic acid comprising a spacer sequence, wherein the spacer sequence comprises at least one deoxyribonucleotide and a plurality of ribonucleotide is claimed. A 2’ hydroxyl group of a ribose on at least one ribonucleotide may be covalently linked to a methyl group (2’-OMe). The gene editing system for use in treating or preventing an atherosclerotic cardiovascular disease, or lowering blood low-density lipoprotein cholesterol (LDL-C) levels or lowering blood triglyceride levels is further claimed. [None]

This invention relates to a method for detecting target nucleic acids based on one-pot isothermal nucleic acid amplification. The invention provides a method for detecting target nucleic acids in a sample, comprising the following steps: a) placing a reaction component and a sample containing the target nucleic acid in the same reaction vessel for amplification reaction, wherein the reaction component comprises i) a single-stranded DNA padlock probe, comprising a first linker region at the 5' end, a second linker region at the 3' end, and an internal reporter region, wherein the first and second linker regions each contain a polynucleotide sequence complementary to the target nucleic acid sequence; optionally, the single-stranded DNA padlock probe is composed entirely of deoxyribonucleotides, or substantially composed of deoxyribonucleotides and containing no more than four consecutive ribonucleotides; ii) a ligase or a variant thereof; iii) a DNA polymerase or a variant thereof with strand displacement activity; and iv) a reaction buffer; b) detecting the amplification reaction product of step a). The invention also provides a kit suitable for the above method.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

Disclosed herein are methods of separating linear polyribonucleotides from a plurality of polyribonucleotides comprising a mixture of linear polyribonucleotides and circular polyribonucleotides, comprising: (a) providing a sample comprising the plurality of polyribonucleotides, wherein the plurality of polyribonucleotides comprises one or more linear polyribonucleotides, each comprising one or more dsRNAs; (b) contacting the sample with a reagent that binds to the dsRNAs; and (c) separating the linear polyribonucleotides comprising the dsRNAs bound to the reagent from the plurality of polyribonucleotides. Also, disclosed herein are a population of circular polyribonucleotides produced by the methods and a pharmaceutical composition containing the circular polyribonucleotides.

The present invention relates to a ribonucleic acid construct capable of inducing an immune response, comprising a double-stranded ribonucleic acid sequence of 8 to 17 ribonucleotides in length, the 5'end of at least one strand of said sequence comprising at least one triphosphoric acid (triphosphoric acid) and on at least one strand of said sequence a single-stranded protruding end, wherein the single-stranded protruding end comprises at least one guanosine. The invention also relates to the use of said constructs as vaccines or as immunoadjuvants, and to ribonucleic acid constructs for use as medicaments or in methods for the treatment or prevention of diseases, in particular in methods for the treatment or prevention of viral infections or cancer. The invention also relates to a pharmaceutical composition and a kit comprising the ribonucleic acid construct.

The present disclosure relates to compositions and methods for separating and / or purifying polyribonucleotides. The polyribonucleotide may be separated from a mixture of polyribonucleotides with a reagent that binds an aptamer on the polyribonucleotide.

The present invention relates to a bioswitchable, embedded miRNA-loaded tetrahedral framework nucleic acid, and a preparation method therefor and the use thereof. In the present invention, miRNA is embedded into a tetrahedral framework nucleic acid (tFNA), and a ribonucleotide is extended at the end of each miRNA strand as a biological switch. Such enzyme-responsive biological switches can be triggered by intracellular RNase H to realize the disassembly of a three-dimensional structure. Moreover, the miRNA comprises a toehold-mediated strand displacement domain, which facilitates the binding of miRNA to an intracellular target, thereby achieving specific cell recognition. The miRNA delivery platform provided by the present invention can effectively treat tumors such as uveal melanoma, and diseases such as acute liver injuries and acute kidney injuries.

The application provides a promoter capable of improving the transcription level of a 5-carboxamidoimidazole ribonucleotide synthetase gene and application, the promoter is based on the sequence shown in SEQ ID NO. 6 and is subjected to mutation, and five promoters capable of strengthening the transcription level of 5-carboxamidoimidazole ribonucleotide synthetase and capable of improving the expression of an alpha-amylase amyE gene from Bacillus subtilis subsp. subtilis str. 168 in coryneform bacteria are obtained.

The present invention is directed to provide novel RNA molecules, chimeric NA molecules, double-stranded RNA molecules, and double-stranded chimeric NA molecules. Specifically, an embodiment of the present invention is an RNA molecule for RNA interference to target a mutant allele with a point mutation, in which (1) the molecule has a nucleotide sequence complementary to a nucleotide sequence of a coding region of the mutant allele; and (2) when counted from the base at the 5′-end in a nucleotide sequence complementary to a nucleotide sequence of the mutant allele, (2-1) a base at position 5 or 6 is mismatched to a base in the mutant allele; (2-2) a position 10 or 11 corresponds to the position of the point mutation; and (2-3) a group at the 2′-position of a pentose at positions 6-8 or positions 7 and 8 is modified with, e.g., OCH3. In this RNA molecule, one or more ribonucleotides may be replaced by, e.g., a deoxyribonucleotide. The molecule may form a double-stranded RNA with a complementary strand.

The present application relates to the field of tumor immunotherapy, discloses a kind of ribozyme for targeted inhibition of PD-L1 gene expression and its preparation method and application, specifically relates to a kind of engineered Pistol ribozyme and its use in targeted inhibition of PD-L1 (CD274) gene expression.The ribozyme is RNA molecule connected by ribonucleotide monomer, contains the substrate recognition region of the conserved structural framework maintaining catalytic activity and PD-L1 transcript complement;Conserved skeleton covers P1, P2, P3 region and false node area, and contains catalytic related conserved base site, substrate recognition region can be designed as required, can recognize and cut the targeted site containing GU dinucleotide in PD-L1 transcript, reduce the PD-L1 expression of tumor cell in post-transcriptional level.The PD-L1 transcript includes mature mRNA, precursor mRNA, intron retention transcript and variable splicing transcript.Different from existing immune checkpoint blockade therapy, the present application can sustainably inhibit endogenous PD-L1 in tumor cell, relieve immune suppression, enhance anti-tumor immune response, and also provide the preparation method of the ribozyme and its pharmaceutical composition, and application prospect is good.